Read this company snapshot
Daily valuation snapshot
United Therapeutics Corp: source evidence dated 2026-10-09.
- Daily close (USD)
- $549.16
- Market capitalization (USD)
- $23,553,852,418.72
- Price / earnings (TTM)
- 17.97
- Price / book
- 3.68
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research UTHR in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research UTHR in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing UTHR with another company.
| Daily close (USD) | $549.16 |
| Market capitalization (USD) | $23,553,852,418.72 |
| Price / earnings (TTM) | 17.97 |
| Price / book | 3.68 |
No matching rows. Clear the filter to see all records.
Read UTHR's valuation metrics
Company size
United Therapeutics Corp's recorded market capitalization is $23,553,852,418.72. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
UTHR's recorded P/E is 17.97: about $17.97 of share price for each $1 of trailing annual earnings per share. Compare that multiple with earnings growth and companies in the same business.
Price relative to book equity
UTHR's recorded price-to-book ratio is 3.68. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research United Therapeutics Corp with Aurora
Use the snapshot above to ask a specific question about UTHR. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow UTHR's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.